title: Suppression of laser-induced choroidal neovascularization by subconjunctival injection of 9alpha-fluoromedroxyprogesterone acetate (FMPA), an anti-angiogenic agent, in rats.
abstract: 9alpha-Fluoromedroxyprogesterone acetate (FMPA) is a synthetic analog of medroxyprogesterone acetate (MPA). FMPA exhibited more potent anti-tumor and anti-angiogenic activities in some assay systems than the parent agent, MPA. Exudative age-related macular degeneration (AMD) is characterized by choroidal neovascularization (CNV). Anecortave acetate, an angiostatic steroid, is clinically efficacious in patients with exudative AMD. Betamethasone is an anti-angiogenic steroid. Therefore, we examined the effects of FMPA, anecortave acetate and betamethasone on laser-induced CNV in rats. Anecortave acetate and betamethasone were included as positive controls. Crypton laser was applied to the fundus in Brown Norway rats. Laser photocoagulations were performed in each eye between the major retinal vessels of the superior retina. Subconjunctival injection of FMPA, anecortave acetate or betamethasone was performed once just after the photocoagulation (on day 0). The incidence of CNV formation was evaluated by fluorescein angiography (FAG) on day 14. On the next day, examination of the retinal function was performed by electro retinogram (ERG). Subconjunctival injection of FMPA at doses of 300, 1000 and 3000 microg/eye dose-dependently inhibited the incidence of CNV formation. Significant differences were observed at doses of 1000 and 3000 microg/eye of FMPA as compared with the control group. Anecortave acetate and betamethasone significantly inhibited the incidence of CNV formation. FMPA at the doses used in this study did not affect the retinal function in rats, as determined by ERG. FMPA appeared to be effective in a rat model of CNV, so it was demonstrated that FMPA might be useful in the treatment of AMD.
authors.affiliation: Pharmaceuticals Development Department, Meiji Dairies Corporation, Tokyo, Japan. natsuko_murata@meiji-milk.com
authors.forename: Natsuko
authors.initials: N
authors.lastname: Murata
authors.forename: Taketo
authors.initials: T
authors.lastname: Yamaji
authors.forename: Masayuki
authors.initials: M
authors.lastname: Uchida
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tsuboi
authors.forename: Hiroto
authors.initials: H
authors.lastname: Suzuki
authors.forename: Masashi
authors.initials: M
authors.lastname: Yamada
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Oikawa
authors.forename: Junko
authors.initials: J
authors.lastname: Nobuhiro
authors.forename: Tominari
authors.initials: T
authors.lastname: Choshi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hibino
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D020256:Choroidal Neovascularization / Q000209:etiology / Q000517:prevention & control*; D003228:Conjunctiva; D004596:Electroretinography; D007834:Lasers; D008297:Male; D011374:Progesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D051381:Rats
chemical_list: C105228:17-acetoxy-9-fluoro-6-methylprogesterone; D020533:Angiogenesis Inhibitors; D011374:Progesterone